Deerfield Management Company, L.P. (Series C) Ascendis Pharma A/S Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $15.4 Million - $19 Million	-144,194 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$62.15 - $129.99 $22.4 Million - $46.9 Million	-360,904 Reduced 71.45%	144,194 $17 Million
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $10.2 Million - $12.9 Million	185,098 Added 57.84%	505,098 $31.6 Million
Q3 2018 Nov 14, 2018	SELL	$63.77 - $76.28 $10.4 Million - $12.4 Million	-162,467 Reduced 33.67%	320,000 $22.7 Million
Q1 2018 May 15, 2018	SELL	$38.98 - $68.04 $11.9 Million - $20.9 Million	-306,533 Reduced 38.85%	482,467 $31.6 Million
Q4 2017 Feb 14, 2018	SELL	$31.98 - $40.38 $1.95 Million - $2.46 Million	-61,000 Reduced 7.18%	789,000 $31.6 Million
Q3 2017 Nov 13, 2017	BUY	$26.89 - $37.1 $22.9 Million - $31.5 Million	850,000	850,000 $30.8 Million

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

Ra Capital Management, L.P. Boston, MA

9.71M
Shares

$1.28 Billion
20.22% of portfolio
Westfield Capital Management CO LP Boston, MA

5.13M
Shares

$674 Million
3.62% of portfolio
Avoro Capital Advisors LLC New York, NY

4.99M
Shares

$655 Million
11.21% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

4.41M
Shares

$579 Million
1.03% of portfolio
Janus Henderson Group PLC London, X0

4.19M
Shares

$550 Million
0.33% of portfolio

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.33B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account